TP
AXSM icon

TritonPoint Partners’s Axsome Therapeutics AXSM Stock Holding History

TritonPoint Partners’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,147
Closed -$209K – 202
2025
Q4 		$209K Buy
+1,147
New +$160K 0.11% 146

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TritonPoint Partners's AXSM Position: Q1 2026 in Review

TritonPoint Partners sold out of Axsome Therapeutics (AXSM) in Q1 2026, closing a stake of 1,147 shares — an estimated $209K sold.

TritonPoint Partners first reported a position in AXSM in Q4 2025 and held it in 1 quarter. The position peaked at $209K in Q4 2025. 410 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • TritonPoint Partners reported no remaining Axsome Therapeutics position as of Q1 2026 after selling out during the quarter.
  • TritonPoint Partners sold 1,147 Axsome Therapeutics shares in Q1 2026, an estimated $209K.
  • TritonPoint Partners first reported a position in Axsome Therapeutics in Q4 2025 and held it in 1 quarter.
  • TritonPoint Partners's Axsome Therapeutics position peaked at $209K in Q4 2025.
  • 410 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on TritonPoint Partners's 13F filing for Q1 2026, filed 28 Apr 2026.